进入Ⅲ期结肠癌个性化风险评估的多维预后时代。
Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer.
作者信息
Rousseau Benoit, Cercek Andrea
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
J Clin Oncol. 2025 May 20;43(15):1751-1754. doi: 10.1200/JCO-25-00205. Epub 2025 Apr 11.
Abstract
In the article that accompanies this editorial, Gallois et al. investigate the added value of transcriptomic signatures incorporating tumoral, stromal and immune features to refine the prognosis assessment of stage III colon cancer after resection. If prospectively validated, these findings pave the way for a personalized adjuvant strategy and possibly omission of adjuvant treatment for patients with very low risk disease or therapeutic intensification for high risk disease.
摘要
在随本社论刊发的文章中，加洛瓦等人研究了整合肿瘤、基质和免疫特征的转录组特征在完善III期结肠癌切除术后预后评估方面的附加价值。如果这些发现得到前瞻性验证，将为个性化辅助治疗策略铺平道路，对于极低风险疾病的患者可能无需进行辅助治疗，而对于高风险疾病的患者则可能加强治疗。
相似文献
1
Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer.进入Ⅲ期结肠癌个性化风险评估的多维预后时代。
J Clin Oncol. 2025 May 20;43(15):1751-1754. doi: 10.1200/JCO-25-00205. Epub 2025 Apr 11.
2
Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer.将林奇综合征纳入Ⅱ期和Ⅲ期结肠癌的个性化预后评估及随访中。
Ann Oncol. 2017 Oct 1;28(10):2620-2621. doi: 10.1093/annonc/mdx292.
3
Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.III 期结肠癌的亚组和预后：辅助治疗的未来展望。
Ann Oncol. 2017 May 1;28(5):958-968. doi: 10.1093/annonc/mdx030.
4
Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al.对Sciallero等人致编辑的信《将林奇综合征纳入II期和III期结肠癌的个性化预后评估及随访》的回复
Ann Oncol. 2017 Nov 1;28(11):2889-2890. doi: 10.1093/annonc/mdx415.
5
Construction of an Immunogenomic Risk Score for Prognostication in Colon Cancer.用于结肠癌预后评估的免疫基因组风险评分构建
Front Genet. 2020 May 21;11:499. doi: 10.3389/fgene.2020.00499. eCollection 2020.
6
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).肿瘤芽殖是 III 期结肠癌患者的独立预后因素：对 IDEA-France III 期试验（PRODIGE-GERCOR）的事后分析。
Ann Oncol. 2022 Jun;33(6):628-637. doi: 10.1016/j.annonc.2022.03.002. Epub 2022 Mar 16.
7
Combining pathological risk factors and T, N staging to optimize the assessment for risk stratification and prognostication in low-risk stage III colon cancer.将病理危险因素与 T、N 分期相结合，以优化低危 III 期结肠癌的风险分层和预后评估。
World J Surg Oncol. 2024 Jan 4;22(1):10. doi: 10.1186/s12957-023-03299-w.
8
Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer.外周血中性粒细胞与淋巴细胞比值可改善结肠癌的预后评估。
Clin Colorectal Cancer. 2017 Jun;16(2):115-123.e3. doi: 10.1016/j.clcc.2017.01.008. Epub 2017 Jan 25.
9
Predictors of recurrence free survival for patients with stage II and III colon cancer.II期和III期结肠癌患者无复发生存的预测因素。
BMC Cancer. 2014 May 16;14:336. doi: 10.1186/1471-2407-14-336.
10
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.评估 6501 例接受氟尿嘧啶、亚叶酸钙和奥沙利铂治疗的 III 期结肠癌患者 10 年期间结局变化：ACCENT 数据库的汇总分析。
Ann Oncol. 2020 Apr;31(4):480-486. doi: 10.1016/j.annonc.2019.12.007. Epub 2020 Jan 16.
本文引用的文献
1
Prediction of overall survival in stage II and III colon cancer through machine learning of rapidly-acquired proteomics.通过快速获取的蛋白质组学的机器学习预测II期和III期结肠癌的总生存期。
Cell Discov. 2024 Aug 13;10(1):85. doi: 10.1038/s41421-024-00707-7.
2
mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial.mFOLFIRINOX 对比 mFOLFOX 6 作为高危 III 期结肠癌辅助治疗 - FROST 试验：一项多中心、随机对照、II 期临床试验的研究方案。
BMC Cancer. 2024 Mar 29;24(1):397. doi: 10.1186/s12885-024-11939-x.
3
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.免疫评分在 III 期结直肠癌中的预后和预测价值：SCOT 和 IDEA-HORG 研究病例的汇总分析。
J Clin Oncol. 2024 Jun 20;42(18):2207-2218. doi: 10.1200/JCO.23.01648. Epub 2024 Mar 14.
4
Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis.利用转录组学进行精准诊断：从癌症和脓毒症中吸取的经验教训。
Front Genet. 2023 Mar 10;14:1100352. doi: 10.3389/fgene.2023.1100352. eCollection 2023.
5
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.循环肿瘤 DNA 分析指导 II 期结肠癌辅助治疗。
N Engl J Med. 2022 Jun 16;386(24):2261-2272. doi: 10.1056/NEJMoa2200075. Epub 2022 Jun 4.
6
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.循环肿瘤 DNA 在 III 期结直肠癌中的应用：超越微小残留病灶检测，评估辅助治疗疗效和复发的临床行为。
Clin Cancer Res. 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. Epub 2021 Oct 8.
7
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer.肿瘤内 CMS 异质性影响局部结肠癌患者预后。
Clin Cancer Res. 2021 Sep 1;27(17):4768-4780. doi: 10.1158/1078-0432.CCR-21-0529. Epub 2021 Jun 24.
8
Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.共识分子亚型在结直肠癌中的临床价值：系统评价和荟萃分析。
J Natl Cancer Inst. 2022 Apr 11;114(4):503-516. doi: 10.1093/jnci/djab106.
9
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.局限性结肠癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2020 Oct;31(10):1291-1305. doi: 10.1016/j.annonc.2020.06.022. Epub 2020 Jul 20.
10
Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer.ACTS-CC试验的5年更新生存率及探索性T x N亚组分析：一项比较S-1与替加氟-尿嘧啶/亚叶酸钙作为Ⅲ期结肠癌辅助化疗的随机对照试验
ESMO Open. 2018 Oct 7;3(6):e000428. doi: 10.1136/esmoopen-2018-000428. eCollection 2018.
Zotero 插件